SQUAMOUS CELL EA3191
Study #EA3191A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent / Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features (ERADICATE)
Back To Clinical Trials NCI Database Entry